BeStock  

Takeda Pharmaceutical TAK

US equityMarket cap rank #310Infectious Disease
$21.77 +$0.36 (+1.68%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $22.09 +1.47%
Open$21.82
Prev close$21.41
Day range$21.74 – $22.07
Volume3.80M
Market cap$69.76B
P/E (TTM)311.0
Dividend yield1.44%

Fundamentals

Latest reported quarter: Q2, ended Sep 2026 · reported in JPY

Revenue¥1.19T+6.7% YoY
Operating profit¥285.14B+195.7% YoY
Net profit¥192.46B+1,740.9% YoY
Diluted EPS¥59.49+1,619.5% YoY
Free cash flow¥248.55B-23.6% YoY
Operating cash flow¥304.27B

Revenue, last 8 quarters

¥1.1TDec '24¥1.1TMar '25¥1.1TJun '25¥1.1TSep '25¥1.2TDec '25¥1.1TMar '26¥1.2TJun '26¥1.2TSep '26

Net profit, last 8 quarters

¥23.8BDec '24¥-103.1BMar '25¥124.3BJun '25¥-11.7BSep '25¥103.7BDec '25¥-368.4BMar '26¥113.3BJun '26¥192.5BSep '26

Diluted EPS by quarter

7.29Dec '24-32.68Mar '2539.12Jun '25-3.92Sep '2532.34Dec '25-117.03Mar '2635.27Jun '2659.49Sep '26

Free cash flow by quarter

¥327.1BDec '24¥129.4BMar '25¥140.4BJun '25¥325.4BSep '25¥150.9BDec '25¥10.1BMar '26¥24.4BJun '26¥248.5BSep '26

Annual revenue

¥3.2TFY21¥3.6TFY22¥4.0TFY23¥4.3TFY24¥4.6TFY25¥4.5TFY26

Profitability & balance sheet

Gross margin65.8%
Operating margin14.3%
Net margin0.9%
Return on equity0.6%
Return on assets0.3%
Return on invested capital1.1%
Current ratio1.15
Liabilities / assets51.4%
Cash & investments¥454.40B
Total debt¥4.58T
Net cash (debt)-¥4.12T
Free cash flow / sales9.2%

Where the revenue comes from

Quarter 2027/Q1

By business line

  • Gastroenterology (GI)¥386.10B 31.7%
  • Plasma Derived Therapies (PDT)¥283.90B 23.3%
  • Rare Diseases¥206.00B 16.9%
  • Oncology¥165.60B 13.6%
  • Neuroscience¥113.60B 9.3%
  • Other¥50.70B 4.2%
  • Vaccines¥14.00B 1.1%

This company reports in its own local currency, not U.S. dollars. Every figure below is labeled with its real currency, not automatically converted.

Income statement

Line item 2027 Q2
(JPY)
2027 Q1
(JPY)
2026 ANNUAL
(JPY)
2026 Q4
(JPY)
2026 Q3
(JPY)
Total Revenue as Reported ¥1.19T ¥1.22T ¥4.51T ¥1.09T ¥1.19T
Total Operating Revenue ¥1.19T ¥1.22T ¥4.51T ¥1.09T ¥1.19T
Cost of Revenue ¥392.09B ¥406.68B ¥1.57T ¥405.70B ¥401.15B
Gross Profit ¥795.00B ¥813.22B ¥2.93T ¥688.84B ¥790.55B
Operating Expense ¥509.86B ¥611.81B ¥2.47T ¥646.77B ¥649.16B
Selling and Admin Expenses ¥271.71B ¥286.51B ¥1.08T ¥292.00B ¥282.78B
Research & Development ¥171.23B ¥167.40B ¥675.92B ¥195.32B ¥175.23B
Depreciation & Amortization & Depletion ¥107.59B ¥110.93B ¥633.54B ¥154.84B ¥141.91B
-Depreciation & Amortization ¥107.59B ¥110.93B ¥633.54B ¥154.84B ¥141.91B
Other Operating Expenses -¥40.67B ¥46.97B ¥76.00B ¥4.62B ¥49.23B
Operating Profit ¥285.14B ¥201.42B ¥464.45B ¥42.07B ¥141.39B
Net Non-Operating Interest Income (Expense) -¥48.81B -¥39.24B -¥143.77B -¥35.88B -¥35.76B
Non-Operating Interest Income ¥14.57B ¥24.61B ¥16.88B -¥189.15B ¥87.87B
Non-Operating Interest Expense ¥63.38B ¥63.85B ¥148.12B -¥165.80B ¥123.63B
Other Income (Expense) -¥80.36B ¥538.00M -¥463.03B -¥461.22B ¥28.23B
Earnings from Equity Interest -¥542.00M ¥538.00M -¥2.18B -¥361.00M ¥799.00M
Pretax Profit ¥155.97B ¥162.72B -¥142.36B -¥455.02B ¥133.86B
Tax -¥36.49B ¥49.46B ¥9.77B -¥86.62B ¥30.13B
Net Profit ¥192.46B ¥113.26B -¥152.13B -¥368.41B ¥103.73B
Profit from Continuing Operations ¥192.46B ¥113.26B -¥152.13B -¥368.41B ¥103.73B
Minority Interests ¥29.00M ¥60.00M ¥264.00M ¥62.00M ¥94.00M
Net Income to Parent Company ¥192.43B ¥113.20B -¥152.39B -¥368.47B ¥103.64B
Net Income to Common Stockholders ¥192.43B ¥113.20B -¥152.39B -¥368.47B ¥103.64B
Basic EPS ¥60.44 ¥35.83 -¥48.38 -¥117.03 ¥32.87
Diluted EPS ¥59.49 ¥35.27 -¥48.38 -¥117.03 ¥32.34
Dividend Per Share ¥0.00 ¥0.00 ¥97.15 ¥49.28 ¥0.00
Total Other Finance Costs – – ¥12.53B – –
Gain on Sale of Security – – ¥6.14B – –
Special Income (Charges) – – -¥466.99B – –
-Less:Restructuring and Mergern & Acquisition – – ¥71.82B – –
-Less:Other Special Charges – – ¥412.23B – –
-Less:Write Off – – ¥1.36B – –
-Gain on Sale Of Business – – ¥18.27B – –
-Gain on Sale of Property/Plant/Equipment – – ¥165.00M – –

Balance sheet

Line item 2027 Q2
(JPY)
2027 Q1
(JPY)
2026 ANNUAL
(JPY)
2026 Q4
(JPY)
2026 Q3
(JPY)
Total Assets ¥15.27T ¥15.66T ¥15.51T ¥15.51T ¥15.41T
Total Current Assets ¥3.00T ¥3.15T ¥3.09T ¥3.09T ¥3.12T
Cash and Cash Equivalents & Short-Term Investments ¥454.40B ¥527.58B ¥636.94B ¥636.94B ¥761.94B
-Cash and Cash Equivalents ¥418.53B ¥460.98B ¥595.05B ¥595.05B ¥654.94B
-Short Term Investments ¥35.87B ¥66.60B ¥41.89B ¥41.89B ¥107.00B
Receivables ¥910.25B ¥956.14B ¥876.35B ¥876.35B ¥757.92B
-Accounts Receivable ¥872.68B ¥930.38B ¥977.36B ¥977.36B ¥736.46B
-Taxes Receivable ¥37.56B ¥25.76B ¥32.04B ¥32.04B ¥21.46B
Inventory ¥1.44T ¥1.45T ¥1.40T ¥1.40T ¥1.41T
Other Current Assets ¥178.08B ¥188.78B ¥162.64B ¥162.64B ¥175.78B
Total Non-Current Assets ¥12.27T ¥12.51T ¥12.42T ¥12.42T ¥12.29T
Net PPE ¥2.28T ¥2.14T ¥2.12T ¥2.12T ¥2.08T
Investments and Advances ¥408.26B ¥473.22B ¥448.74B ¥448.74B ¥434.17B
-Available for Sale Securities ¥399.64B ¥463.14B ¥439.94B ¥439.94B ¥423.98B
-Long Term Equity Investment ¥8.62B ¥10.08B ¥8.80B ¥8.80B ¥10.19B
Goodwill and Other Intangible Assets ¥8.90T ¥9.28T ¥9.23T ¥9.23T ¥9.27T
-Goodwill ¥5.68T ¥5.89T ¥5.81T ¥5.81T ¥5.75T
-Other Intangible Assets ¥3.22T ¥3.39T ¥3.42T ¥3.42T ¥3.52T
Non-Current Deferred Assets ¥607.52B ¥539.15B ¥546.26B ¥546.26B ¥427.49B
Other Non-Current Assets ¥74.10B ¥80.30B ¥77.01B ¥77.01B ¥77.80B
Total Liabilities ¥7.85T ¥8.10T ¥8.08T ¥8.08T ¥7.76T
Total Current Liabilities ¥2.60T ¥2.76T ¥2.83T ¥2.83T ¥2.61T
Payables ¥603.28B ¥564.72B ¥589.23B ¥589.23B ¥615.93B
-Accounts Payable ¥486.20B ¥446.78B ¥324.37B ¥324.37B ¥467.59B
-Total Tax Payable ¥117.08B ¥117.93B ¥97.88B ¥97.88B ¥148.34B
Short-Term Debt and Capital Lease Obligation ¥400.97B ¥519.97B ¥512.16B ¥512.16B ¥583.15B
-Current Debt ¥400.97B ¥519.97B ¥512.16B ¥512.16B ¥583.15B
Current Provisions ¥962.14B ¥995.05B ¥998.50B ¥998.50B ¥572.13B
Other Current Liabilities ¥637.16B ¥684.81B ¥732.19B ¥732.19B ¥838.98B
Total Non-Current Liabilities ¥5.25T ¥5.34T ¥5.25T ¥5.25T ¥5.15T
Long Term Debt and Capital Lease Obligation ¥4.17T ¥4.42T ¥4.37T ¥4.37T ¥4.27T
-Long Term Debt ¥4.17T ¥4.42T ¥4.37T ¥4.37T ¥4.27T
Non-Current Liabilities ¥34.38B ¥37.93B ¥37.55B ¥37.55B ¥34.06B
Non-Current Deferred Liabilities ¥24.29B ¥27.04B ¥26.80B ¥26.80B ¥31.28B
Employee Benefits ¥132.19B ¥141.79B ¥143.68B ¥143.68B ¥150.60B
Other Non-Current Liabilities ¥885.24B ¥713.09B ¥671.07B ¥671.07B ¥665.12B
Total Equity ¥7.42T ¥7.56T ¥7.43T ¥7.43T ¥7.64T
Stockholders' Equity ¥7.42T ¥7.56T ¥7.43T ¥7.43T ¥7.64T
Capital Stock ¥1.72T ¥1.70T ¥1.70T ¥1.70T ¥1.69T
-Common Stock ¥1.72T ¥1.70T ¥1.70T ¥1.70T ¥1.69T
Additional Paid-In Capital ¥1.76T ¥1.79T ¥1.78T ¥1.78T ¥1.75T
Retained Earnings ¥859.25B ¥667.01B ¥712.38B ¥712.38B ¥1.10T
Less: Treasury Stock -¥20.91B -¥47.44B -¥49.13B -¥49.13B -¥49.12B
Gains/Losses Not Affecting Retained Earnings -¥3.22B -¥11.06B -¥2.85B -¥2.85B -¥2.94B
Other Equity Interests ¥3.10T ¥3.46T ¥3.30T ¥3.30T ¥3.15T
Minority Interests ¥991.00M ¥989.00M ¥1.21B ¥1.21B ¥1.15B
-Other Receivables – – ¥36.29B ¥36.29B –
-Receivables Adjustments Allowances – – -¥169.33B -¥169.33B –
-Gross PPE – – ¥3.65T ¥3.65T –
-Accumulated Depreciation – – -¥1.53T -¥1.53T –
-Other Payable – – ¥166.98B ¥166.98B –
Long Term Accounts Payable and Other Payables – – – – ¥3.27B

Cash flow

Line item 2027 Q2
(JPY)
2027 Q1
(JPY)
2026 ANNUAL
(JPY)
2026 Q4
(JPY)
2026 Q3
(JPY)
Operating Cash Flow ¥304.27B ¥127.62B ¥1.04T ¥74.53B ¥373.25B
Net cash flow from continuing operations ¥304.27B ¥127.62B ¥1.04T ¥74.53B ¥373.25B
Net Income from Continuing Operations ¥192.46B ¥113.26B -¥152.13B -¥368.41B ¥103.73B
Gain/Loss from Continuing Operations ¥9.38B -¥6.54B -¥13.02B ¥1.82B -¥441.00M
Depreciation & Depletion & Amortization ¥164.43B ¥163.04B ¥721.13B ¥163.87B ¥190.64B
Deferred Tax -¥36.49B ¥49.46B ¥9.77B -¥86.62B ¥30.13B
Other Non-Cash Items ¥2.38B -¥44.76B ¥228.84B ¥106.40B ¥85.09B
Change in Working Capital ¥11.69B -¥181.57B ¥199.91B ¥251.00B -¥39.33B
-Change in Receivables ¥40.65B -¥70.97B -¥70.17B -¥97.52B -¥10.94B
-Change in Inventory -¥42.25B -¥33.41B -¥61.29B ¥18.70B -¥37.96B
-Change in Payables and Accrued Expense ¥9.27B -¥22.91B -¥3.15B ¥4.80B ¥3.29B
-Change in Other Current Liabilities ¥6.34B -¥34.91B -¥81.61B -¥96.37B ¥20.07B
-Change In Other Working Capital -¥2.33B -¥19.38B ¥416.12B ¥421.38B -¥13.79B
Net cash flow from investing -¥21.07B -¥87.70B -¥369.14B -¥58.02B -¥229.80B
Net Cash Flow from Continuing Investing Activities -¥21.07B -¥87.70B -¥369.14B -¥58.02B -¥229.80B
Net PPE Purchase and Sale -¥44.33B -¥52.72B -¥169.55B -¥46.31B -¥41.62B
Net Intangibles Purchase and Sale -¥11.03B -¥49.43B -¥238.66B -¥18.03B -¥180.74B
Net Business Purchase and Sale ¥12.07B ¥10.46B ¥33.58B ¥515.00M ¥3.36B
Net Investment Purchase and Sale ¥17.03B -¥747.00M -¥10.40B ¥723.00M -¥13.37B
Net Other Investing Changes ¥698.00M -¥244.00M -¥2.78B -¥51.00M -¥2.64B
Financing Cash Flow -¥311.02B -¥180.35B -¥496.82B -¥77.49B -¥192.45B
Net Cash Flow from Continuing Financing Activities -¥311.02B -¥180.35B -¥496.82B -¥77.49B -¥192.45B
Net Issuance Payments Of Debt -¥250.02B -¥11.29B ¥1.08B -¥25.62B -¥9.89B
Net Common Stock Issuance ¥0.00 -¥1.01B -¥51.60B ¥0.00 ¥0.00
Cash Dividends Paid -¥7.73B -¥150.13B -¥311.90B -¥8.79B -¥149.03B
Net Other Financing Charges -¥2.40B -¥2.35B -¥13.01B -¥3.79B -¥3.74B
Ending Cash Balance ¥418.53B ¥460.98B ¥595.05B ¥595.05B ¥654.94B
Net Change in Cash -¥27.83B -¥140.43B ¥175.47B -¥60.98B -¥48.99B
Beginning Cash Balance ¥460.98B ¥595.05B ¥385.11B ¥654.94B ¥681.49B
Effect of Exchange Rate Changes -¥14.62B ¥6.36B ¥34.47B ¥1.10B ¥22.44B
Free Cash Flow ¥248.55B ¥24.39B ¥626.77B ¥10.14B ¥150.88B

Discussion

No comments yet — be the first to weigh in on TAK.

Sign in to join the discussion.

Scroll to Top